BARNETT INTERNATIONAL AND THE UPPSALA MONITORING CENTRE/ WORLD HEALTH ORGANIZATION COLLABORATING CENTRE FOR INTERNATIONAL DRUG MONITORING SUCCESSFULLY TEST GRAPHICAL COMPARISON OF ADVERSE DRUG REACTION DATA
PHILADELPHIA, PA, January 8, 2003 — Barnett International, a subsidiary of PAREXEL International Corporation (NASDAQ: PRXL), has successfully tested an innovative graphical display of adverse drug reaction (ADR) data with the World Health Organization’s (WHO) Collaborating Centre for International Drug Monitoring in Uppsala, Sweden.
Steve Jolley, Principal Consultant, Barnett International states, "This novel approach provides pharmaceutical companies with a way to detect ADR signals as early as possible. The display allows a company to compare their known ADR data for a drug with data from the WHO’s database." Comparisons can be made by company drug, drug class, or all drugs in the database. Currently, the WHO database contains nearly 3 million reports from 70 countries around the world.
Barnett International uses Spotfire Inc.’s DecisionSite™, to select and display data. Selection criteria include adverse reaction terms, body systems, age, sex, dose, country, indication, seriousness, severity, expectedness and causality. By applying combinations of these selection criteria to company data, users can compare the incidence of adverse reactions reported to the company with those in the WHO database. With these comparisons, users can then investigate ADR trends over time.
Perceptive Informatics, Inc., another of PAREXEL’s subsidiaries, integrates DecisionSite™ into its web-based portal products and distributes the combined offering with a goal toward improving the speed and accuracy of decision-making throughout the stages of drug development. The integrated offering allows users to perform interactive visualization and information analysis to uncover key trends in bio/pharmaceutical research. The flexible data visualization capability of DecisionSite™ paired with the robust Perceptive Portal™ creates a powerful signal detection system.
About Barnett International
Barnett International has the benefit of being a division of PAREXEL International, LLC, which is a subsidiary of PAREXEL International Corporation, one of the largest biopharmaceutical outsourcing organizations in the world, providing a broad range of knowledge-based contract research, medical marketing and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. With a commitment to providing solutions that expedite time-to-market and peak market penetration, PAREXEL has developed significant expertise in clinical trials management, data management, biostatistical analysis, medical marketing, clinical pharmacology, regulatory and medical consulting, industry training and publishing and other drug development consulting services. Its information technology subsidiary, Perceptive Informatics, Inc., provides a variety of technology products and services, including web-based portal solutions and voice and data systems, which are designed to accelerate and enhance the clinical development and launch processes. The Company’s integrated services, therapeutic area depth and sophisticated information technology, along with its experience in global drug development and product launch services, represent key competitive strengths. Headquartered near Boston, MA, PAREXEL operates in 57 locations throughout 37 countries around the world, and has approximately 4,860 employees.
About the Uppsala Monitoring Centre
The Uppsala Monitoring Centre (UMC), based in Uppsala, Sweden, is the field-name of the World Health Organization Collaborating Centre for International Drug Monitoring. It is the principal, independent scientific group in the world concerned with the safer, more rational use of medicines and with broader issues of safety in healthcare. The core activity of the UMC, worldwide Pharmacoviglance, is the collecting, researching, assessing and evaluating of information on the adverse effects of medicines, biological products, herbals and traditional medicines with a view to identifying new information about hazards, and preventing harm to patients. The UMC’s authority is based on more than thirty years of scientific research and achievement in collaboration with member countries of the WHO Programme for International Drug Monitoring
This release contains "forward-looking" statements regarding future results and events, including statements regarding the Company’s existing capital resources and future cash flows from operations, and statements regarding expected financial results, future growth and customer demand that involve a number of risks and uncertainties. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes", "anticipates", "plans", "expects", "intends", "appears", “estimates”, “projects” and similar expressions are intended to identify forward-looking statements. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the cancellation, revision, or delay of contracts, including those contracts in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; government regulation of certain industries and clients; competition and consolidation within the pharmaceutical industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic and political risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Form 10-Q for the fiscal quarter ended September 30, 2002, as filed with the Securities and Exchange Commission, which “Risk Factors” discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company’s estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.
DecisionSite is a [registered] trademark of Spotfire Inc.